From clinical experience, cancer patients bearing high tumor mutational load, abundant pre-treatment tumor-infiltrating T cells, and high tumoral expression of pre-treatment PD-L1 are particularly responsive to anti-PD-1/PD-L1 therapy [3]. This evidence concerns the gene CD274 and neoplasm.